Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA

by Zacks Equity Research

Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.

    Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources

    by Zacks Equity Research

    Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources

      Bayer Announced Positive Data for Cancer Drug Copanlisib

      by Zacks Equity Research

      Bayer Aktiengesellschaft (BAYRY) announced positive data on its experimental candidate copanlisib.

        GlaxoSmithKline Initiates Phase III Study with Mepolizumab

        by Zacks Equity Research

        GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).

          BioDelivery to Grant New Patents for its Marketed Drugs

          by Zacks Equity Research

          BioDelivery Sciences (BDSI) recently announced its decision to grant two new patents to extend the patent life for all three of its marketed products, Belbuca , Bunavail, and Onsolis.

            Tirthankar Chakraborty headshot

            5 Stocks with Solid Efficiency Ratio to Buy in April

            by Tirthankar Chakraborty

            Efficiency level is often considered to be an important parameter to find out whether a company has the potential to rake in handsome returns.

              Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate

              by Zacks Equity Research

              Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients.

                Roche's Rituxan Gets FDA Advisory Committee's Recommendation

                by Zacks Equity Research

                Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.

                  Bill Ackman Apologizes for Valeant Investment Error

                  by Zacks Equity Research

                  In a letter addressed to shareholders, Bill Ackman, chairman of Perishing Square Holdings, Ltd stated that investing in Valeant Pharmaceuticals (VRX) was a big mistake on his part.

                    Acorda Presents Data for Parkinson's Candidate CVT-301

                    by Zacks Equity Research

                    Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.

                      Amgen's Leukemia Drug Accepted for Priority Review by FDA

                      by Zacks Equity Research

                      Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.

                        Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

                        by Zacks Equity Research

                        Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

                          Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

                          by Zacks Equity Research

                          Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.

                            Corcept (CORT) Strives to Commercialize Key Drug Korlym

                            by Zacks Equity Research

                            We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.

                              Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III

                              by Zacks Equity Research

                              Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.

                                Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

                                by Zacks Equity Research

                                Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.

                                  Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

                                  by Zacks Equity Research

                                  Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

                                    Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula

                                    by Zacks Equity Research

                                    TESARO, Inc. (TSRO) recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula for ovarian cancer in women.

                                      Will Endo's Troubles Continue to Dent Performance in 2017?

                                      by Zacks Equity Research

                                      2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.

                                        Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

                                        by Zacks Equity Research

                                        Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

                                          Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

                                          by Zacks Equity Research

                                          Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.

                                            Why Heska Corporation (HSKA) Could Be an Impressive Growth Stock

                                            by Zacks Equity Research

                                            Heska Corporation (HSKA) stock has a double digit earnings growth prospect and an impressive Zacks Rank that might bring to the analysts better days ahead for HSKA

                                              Merrimack (MACK) Starts Enrollment in Solid Tumors Study

                                              by Zacks Equity Research

                                              Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.

                                                Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

                                                by Zacks Equity Research

                                                Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                                                  Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

                                                  by Zacks Equity Research

                                                  Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).